To determine if the antibodies could be used for RIT of c-kit-expressing tumors, we evaluated the long-term biodistribution of 111In-labeled antibodies, from which the tumor absorbed dose was estimated for 90Y-labeled corresponding antibodies. Here, KIT is linked to neoplasm.